SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Vicarious Surgical (RBOT) — Oct 20, 2021

Vicarious Surgical Inc.
Date: Oct. 20, 2021 · CIK: 0001812173 · Accession: 0000000000-21-012717

AI Filing Summary & Sentiment

File numbers found in text: 333-260281

Date
October 20, 2021
Author
Not clearly detected
Form
UPLOAD
Company
Vicarious Surgical Inc.

Letter

United States securities and exchange commission logo October 20, 2021 Adam Sachs Chief Executive Officer Vicarious Surgical Inc. 78 Fourth Avenue Waltham, Massachusetts 02451 Re:Vicarious Surgical Inc. Registration Statement on Form S-1 Filed October 15, 2021 File No. 333-260281 Dear Mr. Sachs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Edwin C. Pease, Esq.

Show Raw Text
United States securities and exchange commission logo
October 20, 2021
Adam Sachs
Chief Executive Officer
Vicarious Surgical Inc.
78 Fourth Avenue
Waltham, Massachusetts 02451
Re:Vicarious Surgical Inc.
Registration Statement on Form S-1
Filed October 15, 2021
File No. 333-260281
Dear Mr. Sachs:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Edwin C. Pease, Esq.